Positions

Overview

  • Dr. deShazo sees patients with a variety of solid tumors and is especially interested in lung and genitourinary malignancies. She has taught medical students Introduction to Clinical Medicine for more than 5 years and was recently selected as one of ten faculty designated as Core Clinical Faculty for the Department of Internal Medicine Residency training program.
  • Principal Investigator On

    Investigator On

  • A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)  awarded by Johns Hopkins University
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • Biomarkers for Detection of Renal Cell Carcinoma  awarded by American Cancer Society, Inc.
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors  awarded by HOOSIER ONCOLOGY GROUP
  • Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma  awarded by HOOSIER ONCOLOGY GROUP
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by MERRIMACK PHARMACEUTICALS, INC.
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by MEDIVATION, INC
  • Private Grant  awarded by ALTOR BIOSCIENCE CORPORATION
  • Private Grant  awarded by ALPHA ONCOLOGY, INC
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by BELLICUM PHARMA
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by EISAI, INC.
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by ARAGON PHARMACEUTICALS
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC.
  • Private Grant  awarded by AGENSYS
  • Private Grant  awarded by EXELIXIS, INC.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by ASTRAZENECA AB
  • Private Grant  awarded by THRESHOLD PHARMACEUTICALS, INC.
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by MIRATI THERAPEUTICS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by Bayer HealthCare
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by MEDIVATION, INC
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by CLOVIS ONCOLOGY
  • Private Grant  awarded by STEM CENTRX
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by HEAT BIOLOGICS
  • Private Grant  awarded by EMD SERONO
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by ACERTA PHARMA B.V.
  • Private Grant  awarded by MEDIVATION, INC
  • Private Grant  awarded by MedImmune
  • Private Grant  awarded by INNOCRIN PHARMACEUTICALS, INC.
  • Private Grant  awarded by STEM CENTRX
  • Private Grant  awarded by CELLDEX THERAPEUTICS, INC.
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by MIRATI THERAPEUTICS, INC.
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by REXAHN PHARMACEUTICALS, INC.
  • Private Grant  awarded by ASTELLAS PHARMA US, INC.
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by PROSTATE CANCER CLINICAL TRIALS CONSORTIUM, LLC
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by REXAHN PHARMACEUTICALS, INC.
  • Private Grant  awarded by CLOVIS ONCOLOGY
  • Private Grant  awarded by ALTOR BIOSCIENCE CORPORATION
  • Private Grant  awarded by ASTELLAS PHARMA US, INC.
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by INNOCRIN PHARMACEUTICALS, INC.
  • Private Grant  awarded by MEDIVATION, INC
  • Private Grant  awarded by ACERTA PHARMA B.V.
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by CLOVIS ONCOLOGY
  • Private Grant  awarded by ASTRAZENECA AB
  • Private Grant  awarded by Bayer HealthCare
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by CALITHERA BIOSCIENCES INC
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by JOUNCE THERAPEUTICS, INC
  • Private Grant  awarded by MEDIVATION, INC
  • Private Grant  awarded by ARCUS BIOSCIENCES INC
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by QED THERAPEUTICS INC
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by IMMUNOMEDICS, INC.
  • Private Grant  awarded by EMD SERONO
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by STRATA ONCOLOGY
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by CHECKMATE PHARMACEUTICALS INC
  • Private Grant  awarded by STRATA ONCOLOGY
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University
  • UAB 1311: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination with OGX-427 in Patients with Relapsed or Refractory Metastatic Urothelial Carcinoma after Receiving a Platinum-Containing Regimen  awarded by HOOSIER ONCOLOGY GROUP
  • UAB 1360: Immune Modulation by Addition of Oral Lenalidomide to Intravesical BCG (Bacille Calmette-Guerrin) for Therapy of Non-Muscle-Invasive Transitional Cell Bladder Cancer  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • UAB 1395 - Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer  awarded by KARMANOS CANCER CENTER
  • UAB 1395: Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs. Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer  awarded by KARMANOS CANCER CENTER
  • UAB 1527 – A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer  awarded by Johns Hopkins University
  • UAB 1661: Randomized Phase II Trial Comparing Sequential First-Line Sunitinib and Second-Line Avelumab Versus First-Line Avelumab and Second-Line Sunitinib for Metastatic Renal Cell Carcinoma: SUAVE Trial  awarded by HOOSIER CANCER RESEARCH NETWORK
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology
  • UAB 1984: Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Receiving Ipilimumab and/or Nivolumab  awarded by CLEVELAND CLINIC FOUNDATION
  • Education And Training

  • UAB Hospital, Internship
  • UAB Hospital, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • Full Name

  • Mollie Deshazo